Our Mission!


 Develop a Vaccine and Therapeutic against Hepatitis E

Hepatitis E (HEV)

Unmet Medical Need

20 millions infections annually

3,4 millions symptomatic cases / annum
(chronic & acute)

70.000 deaths

3.000 stillbirths / annum

up to 25% mortality rate in pregnant women, and poor fetal outcomes



Investment Opportunity

Right now we are out there to look for potential Partners! If you are interested feel free to contact us at any time!

  • to secure the preclinical development
  • to prepare clinical development of our lead products
  • to complete at least one Phase 1 trial
  • value-driving milestones will increase our valuation significantly in the next 6 years
  • trade sale or license deals are likely and attractive exit scenarios

Bitte die für das Benutzerkonto hinterlegte E-Mail-Adresse eingeben. Der Benutzername wird dann an diese E-Mail-Adresse geschickt.


Hepatitis is a general term meaning inflammation of the liver and can be caused by a variety of different viruses such as hepatitis A, B, C, D and E. Since the presentation of icterus or jaundice is a characteristic symptom of liver disease, a specific diagnosis of infection by a hepatitis virus can only be made by testing patients' sera for the presence of specific viral antigens, nucleic acid sequences and/or anti-viral antibodies.
Hepatitis E was not recognized as a significant human disease until 1980, when specific tests for antibody against hepatitis A were first applied to the study of epidemic waterborne hepatitis in India. The results showed that the epidemics were not due to hepatitis A; indeed, very few epidemics of waterborne disease in developing countries of Asia and Africa have been linked to hepatitis A.
The first experimental evidence for the existence of an additional waterborne hepatitis agent was reported in 1983[1]. This form of non-A, non-B hepatitis came to be known as Enterically Transmitted non-A non-B hepatitis (ET-NANB), Epidemic non-A non-B hepatitis (ENANB), or faecal-oral non-A non-B hepatitis, and the agent of this disease was subsequently found to be the major cause of sporadic hepatitis cases in regions where the epidemic disease was known to appear.
[1] Balayan MS, et al. (1983) Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 20:23-31.

From the Past to the Future

Lady Montagu was a true pioneer of her time. Our main goal at MVT-Biotechnology is to develop a vaccine and therapeutic for Hepatitis E.


  • Well established vaccine technology
  • Start Clinical PH1 in less than 6 years


  • Travellers and populations in endemic regions
  • Young women, (pre) childbearing age in developed & developing countries
  • Young men/adolescents
  • At-risk groups: animal husbandry, food-chain workers, students


  • Reduce mortality and morbidity
  • Faster resolution and return-to-work
  • Therapeutic for at-risk groups (immunocompromised, transplant patients etc)

Montegu Vaccine & Therapeutics

to prevent and cure